4D Molecular Therapeutics (FDMT) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Surrozen (SRZN) has outperformed 4D Molecular Therapeutics (FDMT) over the past year, gaining 115.6% versus a loss of 5.6%. Over five years, FDMT leads with a -53.6% price change compared with -79.0% for SRZN. Surrozen is the larger company by market cap ($596.4 million vs $576.8 million), about 1.0 times the size, while 4D Molecular Therapeutics is growing revenue faster (+230194.6% vs -67.4%).
4D Molecular Therapeutics converts more of its revenue into profit, with a net margin of -164.4% versus -6960.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FDMT | SRZN |
|---|---|---|
| Share price | $10.23 | $28.46 |
| Market cap | $576.76M | $596.40M |
| 1-day change | -4.57% | -7.21% |
| YTD return | +36.40% | +25.93% |
| 1-year return | -5.63% | +115.61% |
| 5-year return | -53.61% | -78.97% |
| EPS (TTM) | $-2.70 | $-41.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $85.21M | $3.48M |
| Revenue growth (YoY) | +230194.59% | -67.37% |
| Net income (latest FY) | $-140.11M | $-242.03M |
| Operating margin | -187.24% | -1210.58% |
| Net margin | -164.43% | -6960.77% |
| 52-week high | $16.93 | $37.83 |
| 52-week low | $6.96 | $12.79 |
| Distance from 52-week high | -39.57% | -24.77% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +174.58% | +123.12% |
| Average volume | 967.00K | 537.16K |
| Shares outstanding | 56.38M | 20.96M |
| Employees | 196 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed FDMT by 121.2 percentage points over the past year.
- 4D Molecular Therapeutics is more profitable, keeping -164.4 cents of every revenue dollar as net income versus -6960.8 cents for Surrozen.
- 4D Molecular Therapeutics grew revenue faster in its latest fiscal year (+230194.59% vs -67.37%).
About 4D Molecular Therapeutics
FDMT stock →4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 196 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
FDMT vs SRZN FAQ
Which is bigger, 4D Molecular Therapeutics or Surrozen?
Surrozen (SRZN) is larger, with a market capitalization of $596.40M compared with $576.76M for 4D Molecular Therapeutics (FDMT).
Which stock has performed better over the past year, FDMT or SRZN?
SRZN returned +115.61% over the past 12 months, compared with -5.63% for FDMT (price return, excluding dividends). Past performance does not predict future results.
Are 4D Molecular Therapeutics and Surrozen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.